Skip to content
Peptigraph home

BPC-157 and Tesamorelin Together: What Is Known

BPC-157 and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Gastric pentadecapeptidePCAC voted 8–6 for 503A (Jul 2026)BPC-157BPC-157, an experimental gastric pentadecapeptide, not an approved drug; human evidence is a few small uncontrolled reports, including complete symptom resolution in 10 of 12 patients in a bladder pilot.[8]Healing & recoveryGHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[17]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 5 results, 2 Oct 2026).

BPC-157 is not FDA approved, and we have no sourced data on combining it with Tesamorelin.
Each component

Side by side

Showing 13 of 14 fields where the two differ. Vial sizes sold are the same or both unknown.

FieldBPC-157Tesamorelin
ClassGastric pentadecapeptideGHRH analog
Also calledBPC, body protection compound, Pentadecapeptide BPC 157tesa, Egrifta
CategoryHealing & recoveryGrowth hormone
FDA statusPCAC voted 8–6 for 503A (Jul 2026)FDA approved (Egrifta)
PCAC vote, Jul 2026PCAC voted 8–6 for the 503A list (Jul 2026); not finalizedNot on the Jul 2026 agenda
WADAProhibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition.Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption.
Anti-doping detection
  • A 2023 method detects BPC-157 and five main metabolites in human urine at very low concentrations.PMID 37959764
  • A 2017 anti-doping lab method detects BPC 157 in urine; the peptide was stable in urine for at least 4 days.PMID 28035768
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-lifeless than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 3658871711 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)
Evidence strengthHuman observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101
Human studies we summarised3 human (0 randomized or controlled) of 24 summarised11 human (11 randomized or controlled) of 12 summarised
Typical study doses
US searches per month301,000 · Most searched165,000 · +188% searches
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)

What people search

  • bpc 157 and tesamorelin50/mo
  • tesamorelin and bpc 15740/mo
  • bpc 157 tesamorelin30/mo
  • tesamorelin bpc 15720/mo
  • tesamorelin with bpc 15710/mo
  • tesamorelin bpc 157 stack10/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  3. 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  4. 4Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
  5. 5Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
  6. 6Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
  7. 7Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
  8. 8Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
  9. 9Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  10. 10An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  11. 11Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  12. 12EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  13. 13The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  14. 14Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  15. 15The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  16. 16PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  18. 18Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org

Found an error? Report a correction.